1
|
Lei R, Liu X, Wu J. Nutrition and melanoma: the contribution of trace elements in onset, progression, and treatment of melanoma. Nutr Rev 2024; 82:1138-1149. [PMID: 37702535 DOI: 10.1093/nutrit/nuad106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/14/2023] Open
Abstract
Melanoma is a highly malignant and drug-resistant disease that imposes a substantial economic burden on the world. There are many studies linking trace elements to diverse types of cancers, including melanoma. This review elucidates the relationship between trace elements exposure and melanoma. It was identified that copper, manganese, selenium, zinc, iron, and many other trace elements were associated with melanoma in humans. In terms of epidemiology, different elements have different correlations with melanoma. These trace elements affect the occurrence and development of melanoma through various mechanisms, such as oxidative stress and the MAPK pathway. The literature on the role of trace elements in the pathogenesis and treatment of melanoma depicts promising prospects for this field.
Collapse
Affiliation(s)
- Rui Lei
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
| | - Xiao Liu
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
| | - Jinfeng Wu
- Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
2
|
Adhikari S, Nath P, Das A, Datta A, Baildya N, Duttaroy AK, Pathak S. A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies. Biomed Pharmacother 2024; 171:116211. [PMID: 38290253 DOI: 10.1016/j.biopha.2024.116211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2023] [Revised: 12/22/2023] [Accepted: 01/22/2024] [Indexed: 02/01/2024] Open
Abstract
Research into cancer therapeutics has uncovered various potential medications based on metal-containing scaffolds after the discovery and clinical applications of cisplatin as an anti-cancer agent. This has resulted in many metallodrugs that can be put into medical applications. These metallodrugs have a wider variety of functions and mechanisms of action than pure organic molecules. Although platinum-based medicines are very efficient anti-cancer agents, they are often accompanied by significant side effects and toxicity and are limited by resistance. Some of the most studied and developed alternatives to platinum-based anti-cancer medications include metallodrugs based on ruthenium, gold, copper, iridium, and osmium, which showed effectiveness against many cancer cell lines. These metal-based medicines represent an exciting new category of potential cancer treatments and sparked a renewed interest in the search for effective anti-cancer therapies. Despite the widespread development of metal complexes touted as powerful and promising in vitro anti-cancer therapeutics, only a small percentage of these compounds have shown their worth in vivo models. Metallodrugs, which are more effective and less toxic than platinum-based drugs and can treat drug-resistant cancer cells, are the focus of this review. Here, we highlighted some of the most recently developed Pt, Ru, Au, Cu, Ir, and Os complexes that have shown significant in vivo antitumor properties between 2017 and 2023.
Collapse
Affiliation(s)
- Suman Adhikari
- Department of Chemistry, Govt. Degree Collage, Dharmanagar, Tripura (N) 799253, India.
| | - Priyatosh Nath
- Department of Human Physiology, Tripura University, Suryamaninagar, West Tripura 799022, India
| | - Alakesh Das
- Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Chennai 603103, India
| | - Abhijit Datta
- Department of Botany, Ambedkar College, Fatikroy, Unakoti 799290, Tripura, India
| | - Nabajyoti Baildya
- Department of Chemistry, Milki High School, Milki, Malda 732209, India
| | - Asim K Duttaroy
- Department of Nutrition, Institute of Medical Sciences, Faculty of Medicine, University of Oslo, Norway.
| | - Surajit Pathak
- Faculty of Allied Health Sciences, Chettinad Academy of Research and Education (CARE), Chettinad Hospital and Research Institute (CHRI), Chennai 603103, India
| |
Collapse
|
3
|
Niu D, Wang D, Fan L, Liu Z, Chen M, Zhang W, Liu Y, Xu J, Liu Y. The copper (II) complex of salicylate phenanthroline inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. ENVIRONMENTAL TOXICOLOGY 2023; 38:1384-1394. [PMID: 36891644 DOI: 10.1002/tox.23771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 02/09/2023] [Accepted: 02/20/2023] [Indexed: 05/18/2023]
Abstract
In the present study, we investigated the antitumor effect and associated molecular mechanisms of the copper (II) complex of salicylate phenanthroline [Cu(sal)(phen)] against hepatocellular carcinoma (HCC). Cu(sal)(phen) inhibited the proliferation of HCC cells (HepG2 and HCC-LM9) and induced apoptosis of HCC cells in a dose-dependent manner by upregulating mitochondrial reactive oxygen species (ROS) production. The expression of the antiapoptotic proteins survivin and Bcl-2 was decreased, while the expression of the DNA damage marker γ-H2 AX and the apoptotic marker cleaved PARP was upregulated with Cu(sal)(phen) treatment. In vivo, the growth of HepG2 subcutaneous xenograft tumors was greatly attenuated by Cu(sal)(phen) treatment. Immunohistochemistry staining showed that the expression of survivin, Bcl-2, and Ki67 in the tumor was downregulated by Cu(sal)(phen). Toxicity experiments with BALB/c mice revealed that Cu(sal)(phen) is a relatively safe drug. Our results indicate that Cu(sal)(phen) possesses great potential as a therapeutic drug for HCC.
Collapse
Affiliation(s)
- Dongqin Niu
- School of Medicine, Jianghan University, Wuhan, China
| | - Dong Wang
- School of Medicine, Jianghan University, Wuhan, China
- Cancer Institute of Jianghan University, Wuhan, China
| | - Limei Fan
- School of Medicine, Jianghan University, Wuhan, China
- Cancer Institute of Jianghan University, Wuhan, China
| | - Zixin Liu
- School of Medicine, Jianghan University, Wuhan, China
| | - Ming Chen
- School of Medicine, Jianghan University, Wuhan, China
| | - Weiran Zhang
- School of Medicine, Jianghan University, Wuhan, China
| | - Yuchen Liu
- School of Medicine, Jianghan University, Wuhan, China
- Cancer Institute of Jianghan University, Wuhan, China
| | - Jinhua Xu
- School of Medicine, Jianghan University, Wuhan, China
- School of Life Science and Technology, Wuhan University of Bioengineering, Wuhan, China
| | - Yunyi Liu
- School of Medicine, Jianghan University, Wuhan, China
- Cancer Institute of Jianghan University, Wuhan, China
| |
Collapse
|
4
|
de Souza ÍP, de Melo ACC, Rodrigues BL, Bortoluzzi A, Poole S, Molphy Z, McKee V, Kellett A, Fazzi RB, da Costa Ferreira AM, Pereira-Maia EC. Antitumor copper(II) complexes with hydroxyanthraquinones and N,N-heterocyclic ligands. J Inorg Biochem 2023; 241:112121. [PMID: 36696836 DOI: 10.1016/j.jinorgbio.2023.112121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 12/28/2022] [Accepted: 01/02/2023] [Indexed: 01/06/2023]
Abstract
Five ternary copper(II) complexes, [Cu2(phen)2(L1)(ClO4)2] (1), [Cu2(phen)2(L1)(DMSO)2](PF6)2 (2), [Cu2(bpy)2(L1)(ClO4)2(H2O)2] (3), [Cu2(dmp)2(L1)(ClO4)2(H2O)2] (4), and [Cu(phen)(L2)]2(ClO4)2 (5), in which phen = 1,10-phenanthroline, bpy = 2,2'-bipyridine, dmp = 2,9-dimethyl-1,10-phenanthroline, H2L1 = 1,4-dihydroxyanthracene-9,10-dione and HL2 = 1-hydroxyanthracene-9,10-dione, DMSO = dimethylsulfoxide, were synthesized and fully characterized. Complex 2 was obtained through the substitution of perchlorate for DMSO. When two hydroxyquinone groups are present, L1 makes a bridge between two Cu(II) ions, which also bind two nitrogens of the respective diimine ligand. The compounds bind to calf thymus DNA and oxidatively cleave pUC19 DNA according to the following order of activity 1 > 4-5 > 3. Furthermore, complexes 1, 3, 4 and 5 inhibit topoisomerase-I activity and the growth of myelogenous leukemia cells with the IC50 values of 1.13, 10.60, 0.078, and 1.84 μmol L-1, respectively. Complexes 1 and 4 are the most active in cancer cells and in DNA cleavage.
Collapse
Affiliation(s)
- Ívina P de Souza
- Departamento de Química, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, 31270-901 Belo Horizonte, MG, Brazil; Departamento de Química, Centro Federal de Educação Tecnológica de Minas Gerais, Avenida Amazonas, 5253, 30421-169 Belo Horizonte, MG, Brazil
| | - Ariane C C de Melo
- Departamento de Química, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, 31270-901 Belo Horizonte, MG, Brazil
| | - Bernardo L Rodrigues
- Departamento de Química, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, 31270-901 Belo Horizonte, MG, Brazil
| | - Adailton Bortoluzzi
- Laboratório de Bioinorgânica e Cristalografia, Universidade Federal de Santa Catarina, Florianópolis, SC 88040-900, Brazil
| | - Simon Poole
- SSPC, the SFI Research Centre for Pharmaceuticals, School of Chemical Science, Dublin City University, Dublin 9, Ireland
| | - Zara Molphy
- SSPC, the SFI Research Centre for Pharmaceuticals, School of Chemical Science, Dublin City University, Dublin 9, Ireland
| | - Vickie McKee
- SSPC, the SFI Research Centre for Pharmaceuticals, School of Chemical Science, Dublin City University, Dublin 9, Ireland; Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark
| | - Andrew Kellett
- SSPC, the SFI Research Centre for Pharmaceuticals, School of Chemical Science, Dublin City University, Dublin 9, Ireland
| | - Rodrigo B Fazzi
- Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo, Avenida Prof. Lineu Prestes, 748, 05508-000 São Paulo, SP, Brazil
| | - Ana M da Costa Ferreira
- Departamento de Química Fundamental, Instituto de Química, Universidade de São Paulo, Avenida Prof. Lineu Prestes, 748, 05508-000 São Paulo, SP, Brazil
| | - Elene C Pereira-Maia
- Departamento de Química, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, 31270-901 Belo Horizonte, MG, Brazil.
| |
Collapse
|